Therapeutics
-
BioArctic Q4 2025 Report Presentation: February 18, 9:30 AM CET
BioArctic will release its Q4 and full-year 2025 financial results on February 18th. This announcement arrives during a dynamic period for Alzheimer’s therapeutics, marked by intense competition and scientific advancements. Investors will be looking for updates on BioArctic’s pipeline, R&D progress, financial health, and strategic outlook in this evolving and crucial market.
-
Defence Therapeutics Opens U.S. Lab in Boston-Cambridge Biotech Hub
Defense Therapeutics Inc. announced the opening of its first U.S. lab in the Boston-Cambridge area. This strategic move expands its R&D efforts within a leading biotech hub, focusing on the Accum® platform for antibody-drug conjugates (ADCs) used in cancer treatment. The Watertown facility provides access to crucial scientific resources and collaboration opportunities. Defense Therapeutics aims to establish a long-term presence in the area, aiming to strengthen its commitment to advancing their platform.
